Functional Medicine · Hormonal Health

The Journal

by Dr. Natasha Ryan, ND

Peptides · Skin & Collagen

GHK-Cu: Injection or Cream? The Copper Peptide, and Which Form the Evidence Supports

3 min read

GHK-Cu is unusual among the compounds discussed here, for a reason that should change how you approach it: this is the one where the topical form has the stronger human evidence, not the injectable.

That inverts the usual assumption — that injecting something must be the serious version and the cream is the consumer version. For this molecule, the opposite is closer to true.

What GHK-Cu is

GHK is a naturally occurring tripeptide — glycine, histidine, lysine — that binds copper with high affinity. It circulates in your plasma, and its levels decline substantially between your twenties and your sixties.

The copper is not incidental. Copper is a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin into functional structure. GHK acts partly as a delivery vehicle, bringing copper where it’s needed for tissue remodeling.

What the research describes

GHK-Cu is one of the most-studied molecules in skin science. Laboratory and cosmetic research has associated it with:

  • Stimulating collagen and elastin synthesis in skin fibroblasts
  • Supporting wound healing and tissue remodeling
  • Antioxidant and anti-inflammatory activity
  • Improvements in skin density, firmness, fine lines, and photodamage in topical studies
  • Interest in hair follicle support

Injection vs. cream

The topical cream has the strongest human evidence, from cosmetic trials measuring skin parameters directly. It acts where you apply it, which for a skin goal is precisely the point. It is also the lower-risk option — no injection, no systemic copper exposure.

The injection is chosen when the goal is systemic tissue support rather than the skin on your face — broader repair, or as part of the Glow stack alongside BPC-157 and TB-500. The human evidence for injectable GHK-Cu is thinner and draws more on general tissue-repair reasoning than on direct trials.

If your goal is facial skin quality, the cream is the evidence-backed choice and I’d start there. If your goal is systemic repair with skin as one component, the injectable enters the conversation. Some protocols use both, targeting different things.

Research suggests women lose a striking share of their skin collagen in the first years after menopause. No cream reverses that alone — but knowing the cause changes what you do about it.

The estrogen story underneath

Skin is an estrogen-responsive organ. Estrogen receptors are abundant in it, and estrogen supports collagen synthesis, skin thickness, hydration, and wound healing.

Which is why skin change in midlife is not gradual in the way people expect. Research indicates the steepest collagen loss occurs in the years immediately following menopause. Women describe looking different within eighteen months, and they are not imagining it.

Any serious approach to midlife skin has to include the hormonal question, adequate protein and the micronutrients collagen synthesis requires, and sun protection — which remains the single highest-yield intervention for skin aging regardless of what else you do.

Frequently Asked Questions

Which should I choose?

For facial skin quality, the topical cream has the better human evidence. For systemic tissue repair, the injectable is the relevant form. Your goal decides.

Can I use both?

Some protocols do, targeting different objectives. That should be designed with your prescribing provider rather than assembled independently.

How long until I see a change?

Collagen remodeling is inherently gradual. Topical cosmetic studies typically measure change over weeks to months, not days.

Does it work with retinoids or vitamin C?

Layering actives is a real consideration and depends on formulation — some combinations are best applied at different times of day. A dermatology-informed routine is worth building deliberately.

Is there a copper safety concern?

With systemic use, yes, it deserves attention — particularly for anyone with a copper metabolism disorder. Topical exposure is far more limited.

References

  1. Pickart L, Margolina A. "Skin Regenerative and Anti-Cancer Actions of Copper Peptides." Cosmetics, 2018. View source
  2. Pickart L, Vasquez-Soltero JM, Margolina A. "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration." BioMed Research International, 2015. View source
  3. Brincat M, et al. "A study of the decrease of skin collagen content, skin thickness, and bone mass in the postmenopausal woman." Obstetrics & Gynecology, 1987. View source
  4. Brincat M, et al. "Decline in skin collagen content and metacarpal index after the menopause and its prevention with sex hormone replacement." BJOG, 1987. View source

Regulatory status was checked against FDA guidance current at the time of publication. Where a compound is investigational, that is stated in the disclosure at the top of this article.